Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADOT - BIOMODA: Profitable Technology with Purpose -- Ignore unavailable to you. Want to Upgrade?

To: JustMy2Cents who wrote (1244)	7/7/1998 10:38:00 AM
From: Brad	Respond to of 4650

JM2C, Great information! Thanks for posting it. The 60 patient study of the TCPP technology >>will be completed by August 1998, and that the results will be of publishable quality.<< When I talked to Biomoda last week, they told me that if they do a deal with ScheringAG/Berlex (possible major pharmaceutical partner mentioned in previous press release), ScheringAG/Berlex would have to commit to the $10 million funding. Of course, ScheringAG/Berlex has an annual budget of $700 million for research of which $175 million is designated for external research & development (R&D) such as Biomoda. Biomoda said they expect possible further developments with ScheringAG/Berlex when they have the 60 patient study completed (mid August). Best wishes, Brad